DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2006/0275801 A1 Henkin (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2006/0275801 A1 Henkin (43) Pub US 20060275801A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0275801 A1 Henkin (43) Pub. Date: Dec. 7, 2006 (54) METHODS FOR DETECTION OF (52) U.S. Cl. .................................................. 435/6; 435/7.1 BOLOGICAL SUBSTANCES (76) Inventor: Robert I. Henkin, Bethesda, MD (US) (57) ABSTRACT Correspondence Address: WILSON SONSN GOODRCH & ROSAT The invention is directed to a method of detecting a bio 650 PAGE MILL ROAD logical Substance in the nasal Secretion and diagnosing a PALO ALTO, CA 94304-1050 (US) disease following the detection of the biological substance (21) Appl. No.: 11/415,942 wherein the biological Substance is not related to a respira tory disease. The invention also provides treatment of the (22) Filed: May 1, 2006 diseases following the detection of the biological Substance and/or diagnosis of the disease. In some embodiments, the Related U.S. Application Data diseases are cancer, hepatitis, Smell loss, taste loss, diabetes, (60) Provisional application No. 60/743,495, filed on Mar. and leprosy. The invention also provides a kit for diagnosing 15, 2006. Provisional application No. 60/676,252, a disease. The present invention includes methods of ana filed on Apr. 29, 2005. lyzing samples from the nose for the detection of biological Substances. In particular, nasal Secretion or nasal mucus is Publication Classification collected and analyzed for biological substances. The results (51) Int. Cl. of this analysis are then Suitable for use in diagnosis, CI2O I/68 (2006.01) prognosis, and determination of Suitability of therapeutic GOIN 33/53 (2006.01) interventions. Patent Application Publication Dec. 7, 2006 Sheet 1 of 12 US 2006/0275801 A1 3.Se3s?p9?,3soufield Patent Application Publication Dec. 7, 2006 Sheet 2 of 12 US 2006/0275801 A1 Z'50||-|| –002 Patent Application Publication Dec. 7, 2006 Sheet 3 of 12 US 2006/0275801 A1 Patent Application Publication Dec. 7, 2006 Sheet 4 of 12 US 2006/0275801 A1 L anes 1-7 HLA M Mol, wt markers 8-14 B-globin FIG. 4 Patent Application Publication Dec. 7, 2006 Sheet 5 of 12 US 2006/0275801 A1 Lp/(-)p-eoueose On Patent Application Publication Dec. 7, 2006 Sheet 6 of 12 US 2006/0275801 A1 P Name Calculate. CrOS. 1 WB POS COnt O.OOOE-00 22.67 2 R. BIk CO.OOOE-00 D41.00 3Specimen it O.OOOE-00 19.02 4 Specimen #2 O.OOOE-00 27.42 5 Speciment:1 + Pos Cont 0.000E+00 18.18 6 Specimen #1 + Pos Cont 0.000E+00 18.62 7 RBIk CO.OOOE-00 D4100 3.5 d2. 0.5O 242 12th- -n - is a < - -0.5 Cycle Number F.G. 6 Patent Application Publication Dec. 7, 2006 Sheet 7 of 12 US 2006/0275801 A1 Patent Application Publication Dec. 7, 2006 Sheet 8 of 12 US 2006/0275801 A1 8 WB POSCOnt 00 9 R. BIK . 0.000E-00 40.28 10 Specimen #1 0.000E+00 28.85 11 Specimen #2 12 Specimen #1 + Pos Cont 0.000E+00 22.13 13 Specimen #1 + Pos Cont 14 R. BIk 2. 5 0.1 -0. 5 Cycle Number FIG. 8 Patent Application Publication Dec. 7, 2006 Sheet 9 of 12 US 2006/0275801 A1 P Name Calculate. CrOS. 1 WBPOS COnt 0.000E+00 22.67 2 RBIK <0.000E+00 D41.00 3 Specimen #1 0.000E--00 19.02 4 Specimen #2 0.000E+00 27.42 5 Specimen #1+Pos Cont 0.000E+00 18.18 6 Specimen #1 + Pos Cont, 0.000E+00 18.62 7 RBIK <0.000E+00 D41.00 8 WBPOS COnt 0.000E+00 24.24 9 RBIK 0.000E+00 40.28 10 Specimen #1 0.000E+00 28.85 11 Specimen #2 12 Speciment:1 + Pos Cont 0.000E+00 22.13 13 Specimen #1 + Pos Cont 14 R. BK 13 12 11 10 9 8 7 3 6 L 5 4 3. 2 1 O O -1 -2 | | | | | | | O 5 10 15 20 25 30 35 40 45 Cycle Number FIG. 9 Patent Application Publication Dec. 7, 2006 Sheet 10 of 12 US 2006/0275801 A1 : 4 SWOLI19?jepueQuojºqeA??esp?oueaJoSISATIVNVSWHOL-ICIT?S :-***************************)009090000G0000x 33.Te?O/ssew …….…••••••••****************Ö000£0000z –?????????????????????????????????????? An a.ISuelu eAlbe Patent Application Publication Dec. 7, 2006 Sheet 11 of 12 US 2006/0275801 A1 x'x?'IIA–BLSVI.TIBOIIIJdÅL-31SVL - }JO?VHBÌN35) TVILNEJ.Od NY/HOeo!-TIJN |-TEWSTIBOTV8-LIW–BTBWS HO_Ld303}} Patent Application Publication Dec. 7, 2006 Sheet 12 of 12 US 2006/0275801 A1 z?‘SH QuB.I0pO/Que?SEJL | US 2006/0275801 A1 Dec. 7, 2006 METHODS FOR DETECTION OF BIOLOGICAL 0007 One aspect of the present invention is method of SUBSTANCES treating a disease wherein the treatment is based on diag nosing the disease, wherein the diagnosis is based on a CROSS-REFERENCE detection of a biological Substance in a nasal specimen, and 0001. This application is related to and claims priority to wherein the biological Substance is not related to a respira U.S. Provisional Application No. 60/743,495, filed Mar. 15, tory disease. In some embodiments, the disease is selected 2006, and U.S. Provisional Application No. 60/676.252, from the group consisting of Smell loss, taste loss, diabetes, filed Apr. 29, 2005, which are incorporated herein by ref obesity, anorexia, cancer, leprosy, and hepatitis. In some erence in their entirety. preferred embodiments, the cancer is ovarian cancer. In Some embodiments, the treatment is selected from the group BACKGROUND OF THE INVENTION consisting of oral administration, transmucosal administra tion, buccal administration, nasal administration, parental 0002 Detection and identification of biological sub administration, intravenous, Subcutaneous, intramuscular, stances in tissue samples is used for the diagnosis, progno Sublingual, transdermal administration, and rectal adminis sis, and monitoring of diseases. Efficient identification of tration. In some preferred embodiments, the treatment is by biological Substances aids in devising effective treatment nasal administration. Further the efficacy of the treatement Strategies. can be monitored by analysis of the nasal specimens. 0003 Most of the current diagnostic techniques involve 0008 Another aspect of the present invention is a method invasive procedures for the removal of tissue samples. of providing a conclusion regarding a disease to a patient, a Hence, there is need for the development of minimally health care provider or a health care manager where the invasive procedures for biological sample retrieval. conclusion is based on a diagnosis, wherein the diagnosis is 0004 The present invention provides methods for detec based on a detection of a biological Substance in a nasal tion of biological Substances, diagnosis of diseases based on specimen, and wherein the biological Substance is not this detection and methods for treatment of the diseases after related to a respiratory disease. the diagnosis. 0009. One aspect of the present invention is a method of diagnosing diabetes in a patient by obtaining a nasal speci SUMMARY OF THE INVENTION men, detecting insulin, insulin receptor or a combination 0005 One aspect of the present invention is a method of thereof in the specimen, and diagnosing the diabetes in the diagnosing a disease by obtaining a nasal specimen, detect patient, wherein the diagnosis is based on the detection of ing a biological Substance in the specimen, and diagnosing insulin, insulin receptor or a combination thereof in the nasal the disease, wherein the diagnosis is based on the detection specimen. Another aspect of the present invention is a of the biological Substance, and wherein the biological method of monitoring an efficacy of a diabetes therapy in a Substance is not related to a respiratory disease. In some patient by obtaining a nasal specimen, detecting insulin, embodiments, the biological Substance is a nucleic acid. In insulin receptor or a combination thereof in the specimen, some preferred embodiments, the nucleic acid is DNA, RNA and determining the efficacy of the diabetes therapy, wherein or a combination thereof. In some embodiments, the detec the determining is based on the detection of the insulin, tion is by a nucleic acid detection method. In some embodi insulin receptor or a combination thereof in the nasal speci ments, the nucleic acid detection method is selected from the C. group consisting of polymerase chain reaction (PCR), ligase 0010. One aspect of the present invention is a method of chain reaction (LCR), Strand displacement amplification diagnosing cancer in a patient by obtaining a nasal speci (SDA), self-sustained sequence replication (3SR), array men, detecting TNFC. in the specimen, and diagnosing the based test, and TAOMAN. In some preferred embodiments, cancer in the patient, wherein the diagnosis is based on the the nucleic acid detection method is PCR. detection of TNFC. in the nasal specimen. Another aspect of 0006. In some embodiments of the present invention, the the present invention is a method of monitoring an efficacy biological Substance is selected from the group consisting of of a cancer therapy by obtaining a nasal specimen, detecting insulin, insulin receptor, leptin, agouti-related protein, ghre TNFC. in the specimen, and determining the efficacy of the lin, glucose, growth factor, caspase, adenylyl cyclase, and cancer therapy, wherein the determining is based on the carbonic anhydrase. In some embodiments, the biological detection of TNFC. in the nasal specimen. Yet another aspect Substance is selected from the group consisting of p53, or of the present invention is a method of treating cancer by mutated p53, TNFO, TNFR I, TNFR II, TRAIL, IL3, obtaining a nasal specimen, detecting TNFC. in the speci endostatin, erythropoietin, bone morphogenic protein, brain men, and administering a drug to the patient, wherein the derived neurotrophic factor, ciliary neurotrophic factor, drug modulates the TNFC.
Load more

Recommended publications
  • Brutalny Napad Brutalny Napad
    18 grudnia 2000 r, Nr 245 (15 387) Plebiscyty Wydanie O NAKŁAD : 44 125 z nagrodami Cena 80 gr • Dł a kogo Laur •• No.';n"~ ;+-'-~ Ukazuje się w Polsce - str. 22. południowo-wschodniej • Jutro lista kandydatów e-mail [email protected] do tytufu" Czlowiek TysIą cl ec ia " • Kto n aj ł e pszym sportowcem? www . nowi ny _ med ia. pł - str. 13. Redaktor prowadzący Finat plebiscy1lów Elżbieta Kolano GAZETA CODZIENNA I PONIEDZIAŁEK - coraz Milczenie kryje Co naprawdę Katarzyna Wójcicka maltretowanie stało się i Paweł Zygmunt , kobiet w grudniu mistrzami w rodzinach. 1970 r. wieloboju. na Wybrzeżu str. 21 str. 6 str. 14 Spotkali się internowani, więźniowie , politycy Nasza chata J u ż jutro wraz z ~ Nowinam iH IJdod~:;~r~~f. bezpłatny Więzienne I ~ N asza Chata", a w nim wiele praktycznych porad • nI.: klejenia tapet i samodzielnego uk ładania paneli rocznice podłogowych , Ponadto dowiesz się o zaletach BARTOSZ B ĄCA l dar n ośc i" za zryw narodowo­ marmuru i granitu ś ciowy . za umożliwieni e wp ro­ naturalnego oraz ZAŁIi:ł:E K . RZESZOWA. wadzeniu kapelanów do w i ę z i eń Sltucznego. L Wczoraj w Zakładzie Karnym - powiedzial ks . bp Edward spotkali się członkowie NSZZ B i a ł ogłow s ki . "Solidarność ". którzy trafili Podczas koncelebrowanej tam po ogłoszeniu stanu wo­ przez niego mszy św , przed­ jennego. Tego samego dnia stawiciele "S" z l ożyli w darze Wyrok na pijanych zakład obchodził 20-lecle ornat do po s ł ugi li turgicznej, funkcjonowania. Potem dzielono s ię opłatk i em , Karanie za j azdę po pijanemu spowoduje tłok w więz i e nia c h .
    [Show full text]
  • School of Medicine 1
    June 28, 2010 School of Medicine 1 • SONYA STEPHENS, Ph.D., Vice Provost for School of Medicine Undergraduate Education • ROGER J. THOMPSON, Ph.D., Vice Provost for Administration Enrollment Services • RICHARD N. McKAIG, Ed.D., Dean of Students and Indiana University Vice President for Student Affairs, Bloomington • MICHAEL A. McROBBIE, Ph.D., President of the University Indianapolis Campus • CHARLES R. BANTZ, Ph.D., Executive Vice • CHARLES R. BANTZ, Executive Vice President and President and Chancellor, Indiana University– Chancellor, Indiana University–Purdue University Purdue University Indianapolis Indianapolis • KAREN HANSON, Ph.D., Executive Vice President • UDAY SUKHATME, Ph.D., Executive Vice and Provost, Indiana University Bloomington Chancellor and Dean of the Faculties • JOHN S. APPLEGATE, Ph.D., Vice President for • TRUDY W. BANTA, Ed.D., Senior Advisor to the Planning and Policy Chancellor for Academic Planning and Evaluation • D. CRAIG BRATER, M.D., Vice President and Dean • DAWN RHODES, M.B.A., Vice Chancellor for and Walter J. Daly Professor, School of Medicine Finance and Administration • J. TERRY CLAPACS, M.B.A., Vice President and • KODY VARAHRMYAN, Ph.D., Vice Chancellor for Chief Administrative Officer Research • DOROTHY J. FRAPWELL, J.D., Vice President and • AMY C. WARNER, M.A., Vice Chancellor for General Counsel External Affairs • G. FREDERICK GLASS, J.D., Vice President and • KAREN M. WHITNEY, Ph.D., Vice Chancellor for Director of Intercollegiate Athletics Student Life and Dean of Students • EDWIN C. MARSHALL, O.D., Vice President for • KENNETH B. DURGANS, Ed.D., Assistant Diversity, Equity, and Multicultural Affairs Chancellor for Diversity, Equity, and Inclusion • PATRICK O’MEARA, Ph.D., Vice President for School of Medicine International Affairs • ORA H.
    [Show full text]
  • LXFDVD Mopslinux 6.0
    LXF97 Python » MySQL » Slashdot » OpenMoko LXFDVD MOPSLinux 6.0 ПЛЮС: ALT Linux 4.0 Personal Desktop LXF Октябрь 2007 » Zenwalk Live & Core » KDE 4 Beta 2 № 10(97) Главное в мире Linux № 1100 Ubuntu ООктябрьктябрь ((97)97) 22007007 БоремсясоSlashdot-эффектом Борьба за лучший Эксклюзивная информация Python о том, как делается самый ParagonNTFS популярный в мире дистрибутив Что нового в Gusty Gibbon? Мнения разработчиков ЛуисСуарес-Поттс ППЛЮС!ЛЮС! Собери свой собственный Ubuntu Mono SedиAwk OpenMoko Пишемсобственныйebuild Не заSlashdot’ишь! Bash, Sed, Awk Ebuild’нем… Подготовьте свой web-сайт к Накоротке с основными инстру- Приготовьте исходный код для наплыву посетителей с. 42 ментами командной строки с. 58 пользователей Gentoo с. 72 ККаталогаталог аагентствагентства «РРОСПЕЧАТЬОСПЕЧАТЬ» – подписной индекс 2208820882 ККаталогаталог «ППРЕССАРЕССА РРОССИИОССИИ» – подписной индекс 8879747974 Я ни на секунду не предлагаю ОOо стать Боргом! OpenOffice.org Луис Суарес-Поттс Приветствие Главное в мире Linux К Вашим услугам... Продав компанию Thawte, основатель Ubuntu Марк Шаттлворт заработал 575 миллионов долларов. А на что бы вы потратили эту сумму, окажись она в вашем распоряжении? Пол Хадсон Грэм Моррисон Майк Сондерс Я бы создал фонд Я бы притворился Я бы проспонсиро- помощи бездомным бездомным ребен- вал строительство детям... а затем ком, чтобы урвать механических без- купил большую, еще и кусок, достав- домных детей, блестящую машину. шийся Полу. чтобы они делали работу, которую сейчас выполняют живые бездомные дети. В плену у технологий Жить без технологий невозможно – по крайней мере, если вы с удовольствием читаете журналы вроде LXF. Компьютеры (как проявление технологий) берут на себя тяжелую и рутинную работу вроде размещения на бумаге символов, которые я сейчас набираю – а вам остается только пожинать плоды заслуженного Эфрейн Эрнандес- Мэтт Нейлон Энди Ченнел Мендоса Я бы вложил один- Я бы закупил мно- бездействия..
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2013/0136768 A1 Picker Et Al
    US 2013 O136768A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0136768 A1 Picker et al. (43) Pub. Date: May 30, 2013 (54) RECOMBINANT HCMV AND RHCMV Publication Classification VECTORS AND USES THEREOF (51) Int. Cl. Applicant: Oregon Health & Science University, CI2N 5/869 (2006.01) (71) A6139/08 (2006.01) Portland, OR (US) A6139/00 (2006.01) A639/2 (2006.01) (72) Inventors: Louis Picker, Portland, OR (US); Jay A. A 6LX39/275 (2006.01) Nelson, Lake Oswego, OR (US); Klaus A639/2I (2006.01) Frueh, Portland, OR (US); Michael A. A639/13 (2006.01) Jarvis, Portland, OR (US); Scott G. A639/45 (2006.01) Hansen, Portland, OR (US) (52) U.S. Cl. CPC .............. CI2N 15/869 (2013.01); A61K 39/13 (2013.01); A61 K39/08 (2013.01); A61 K Assignee: Oregon Health & Science University, 39/145 (2013.01); A61 K39/12 (2013.01); (73) A61K 39/275 (2013.01); A6IK 39/21 Portland, OR (US) (2013.01); A61 K39/00II (2013.01) USPC ..................................... 424/199.1: 435/320.1 (21) Appl. No.: 13/694,280 (57) ABSTRACT Described herein are recombinant rhesus cytomegalovirus (RhCMV) and human cytomegalovirus (HCMV) vectors encoding heterologous antigens, such as pathogen-specific (22) Filed: Nov. 14, 2012 antigens or tumor antigens. The recombinant vectors elicit and maintain high level cellular and humoral immune responses specific for the heterologous antigen. The recom Related U.S. Application Data binant RhCMV and HCMV vectors may be used, for example, for the treatment or prevention of infectious disease (63) Continuation-in-part of application No.
    [Show full text]
  • Dynamically Registering C++ Exception Handlers: Centralized Handling of C++ Exceptions in Application Framework Libraries
    Dynamically Registering C++ Exception Handlers: Centralized Handling of C++ Exceptions in Application Framework Libraries by Nathaniel H. Daly A thesis submitted in partial fulfillment of the requirements for the degree of Bachelor of Science (Honors Computer Science) in the University of Michigan 2013 Thesis Committee: Professor David Kieras, Advisor Professor David Paoletti, Second Reader Abstract The C++ exceptions mechanism enables modularized programs to separate the reporting of exceptional conditions from the handling of those exceptional condi- tions into the locations where those actions can best be performed. It is often the case in such modular applications that the module capable of detecting an excep- tional situation cannot know how it should be handled, and so C++ exceptions allow the module that invoked the operation to react to the condition. Libraries developed separately from the applications using them are a perfect example of modularized code, and thus a perfect candidate for using C++ exceptions, how- ever many of the application framework library paradigms that have become commonplace do not provide adequate exception support to allow for good pro- gramming style with regard to catching and handling exceptions. In these librar- ies, there often exist multiple callback-style entry points that invoke application- specific operations, all of which require exactly identical exception handling, yet there is no way to collect this code together. Instead, the exception handling code must be duplicated across each entry point. In this paper, I will explore the best solutions to this problem currently provided by such frameworks; I will propose an additional solution to this problem: a method for allowing a program to regis- ter exception-handler operations templated by exception type; and finally, I will identify any impacts that the newly released C++11 standard and the currently evolving C++14 standard have on the problem.
    [Show full text]
  • Eee", Rpen. E. 632. A
    USOO9506920B2 (12) United States Patent (10) Patent No.: US 9,506.920 B2 Singh et al. (45) Date of Patent: *Nov. 29, 2016 (54) ASSAYS FOR THE DETECTION OF 5,698,419 A 12/1997 Wolpe et al. ANT-TNF DRUGS AND AUTOANTIBODES 5,795,967 A 8/1998 Aggarwal et al. 5,837,242 A 11/1998 Holliger et al. 6,284.471 B1 9, 2001 Le et al. (71) Applicant: NESTEC S.A., Vevey (CH) 6,309,888 B1 10/2001 Holvoet et al. 6,444,461 Bl 9/2002 Knapp et al. (72) Inventors: Sharat Singh, Rancho Santa Fe, CA 6,906,183 B2 * 6/2005 Romisch ................ CO7K 14,76 (US); Shui Long Wang, San Diego, 530,363 CA (US); Linda Ohrmund, San Diego, 7,189,515 B2 3/2007 Buechler et al. 7,276.477 B2 10/2007 Osslund et al. CA (US) 7,524,502 B2 4/2009 Hellendoorn et al. 7,601,335 B2 10/2009 McCutcheon et al. (73) Assignee: Nestec S.A., Vevey (CH) 7,662,569 B2 2/2010 Targan et al. 8,574,855 B2 11/2013 Singh et al. (*) Notice: Subject to any disclaimer, the term of this 8,865,417 B2 10/2014 Singh et al. 2003/0040.027 A1 2/2003 Ritter et al. patent is extended or adjusted under 35 2003/0077246 A1 4, 2003 Welcher et al. U.S.C. 154(b) by 63 days. 2004/0022792 A1 2/2004 Klinke et al. This patent is Subject to a terminal dis- 2004/O157782 A1* 8, 2004 Doronina ................
    [Show full text]
  • Py++ Documentation Release 1.9.0
    Py++ Documentation Release 1.9.0 Roman Yakovenko Nov 02, 2017 Contents 1 Code generation process 3 1.1 “read declarations” ...........................................3 1.2 “build module” ..............................................3 1.3 “write code to files” ...........................................4 2 Features list 5 3 License 7 4 Documentation contents 9 4.1 Tutorials.................................................9 4.2 Users and quotes............................................. 70 4.3 Download & Install........................................... 72 4.4 Examples................................................. 73 4.5 Architecture............................................... 73 4.6 Boost.Python - lessons learned...................................... 77 4.7 Development history........................................... 109 4.8 API.................................................... 118 4.9 How to ... ?................................................ 120 5 Indices and tables 129 i ii Py++ Documentation, Release 1.9.0 Py++ is an object-oriented framework for creating a code generator for Boost.Python library and ctypes package. Py++ uses few different programming paradigms to help you to expose C++ declarations to Python. This code generator will not stand on your way. It will guide you through the whole process. It will raise warnings in the case you are doing something wrong with a link to the explanation. And the most important it will save your time - you will not have to update code generator script every time source code is changed. Contents 1 Py++ Documentation, Release 1.9.0 2 Contents CHAPTER 1 Code generation process Code generation process, using Py++ consists from few simple steps. 1.1 “read declarations” Py++ does not reinvent the wheel. It uses Clang C++ compiler to parse C++ source files. To be more precise, the tool chain looks like this: 1. source code is passed to CastXML 2. CastXML passes it to Clang C++ compiler 3.
    [Show full text]
  • Py++ Documentation Release 1.8.0
    Py++ Documentation Release 1.8.0 Roman Yakovenko Sep 14, 2017 Contents 1 Code generation process 3 2 “read declarations” 5 3 “build module” 7 3.1 “write code to files” ...........................................8 4 Features list 9 5 License 11 6 Documentation contents 13 6.1 Tutorials................................................. 13 6.2 Users and quotes............................................. 19 6.3 Download & Install........................................... 21 6.4 Examples................................................. 21 6.5 Links................................................... 27 6.6 Compare Py++ to .............................................. 28 6.7 TODO.................................................. 34 6.8 Boost.Python - lessons learned...................................... 37 6.9 Development history........................................... 69 6.10 API.................................................... 78 7 Indices and tables 85 i ii Py++ Documentation, Release 1.8.0 Py++ is an object-oriented framework for creating a code generator for Boost.Python library and ctypes package. Py++ uses few different programming paradigms to help you to expose C++ declarations to Python. This code generator will not stand on your way. It will guide you through the whole process. It will raise warnings in the case you are doing something wrong with a link to the explanation. And the most important it will save your time - you will not have to update code generator script every time source code is changed. Contents 1 Py++ Documentation, Release 1.8.0 2 Contents CHAPTER 1 Code generation process Code generation process, using Py++ consists from few steps. The following paragraphs will tell you more about every step. 3 Py++ Documentation, Release 1.8.0 4 Chapter 1. Code generation process CHAPTER 2 “read declarations” Py++ does not reinvent the wheel. It uses GCC C++ compiler to parse C++ source files.
    [Show full text]
  • School of Medicine Undergraduate Education • ROGER J
    July 13, 2011 1 • SONYA STEPHENS, Ph.D., Vice Provost for School of Medicine Undergraduate Education • ROGER J. THOMPSON, Ph.D., Vice Provost for Administration Enrollment Services • RICHARD N. McKAIG, Ed.D., Dean of Students and Indiana University Vice President for Student Affairs, Bloomington • MICHAEL A. McROBBIE, Ph.D., President of the University Indianapolis Campus • CHARLES R. BANTZ, Ph.D., Executive Vice • CHARLES R. BANTZ, Executive Vice President and President and Chancellor, Indiana University– Chancellor, Indiana University–Purdue University Purdue University Indianapolis Indianapolis • KAREN HANSON, Ph.D., Executive Vice President • UDAY SUKHATME, Ph.D., Executive Vice and Provost, Indiana University Bloomington Chancellor and Dean of the Faculties • JOHN S. APPLEGATE, Ph.D., Vice President for • TRUDY W. BANTA, Ed.D., Senior Advisor to the Planning and Policy Chancellor for Academic Planning and Evaluation • D. CRAIG BRATER, M.D., Vice President and Dean • DAWN RHODES, M.B.A., Vice Chancellor for and Walter J. Daly Professor, School of Medicine Finance and Administration • J. TERRY CLAPACS, M.B.A., Vice President and • KODY VARAHRMYAN, Ph.D., Vice Chancellor for Chief Administrative Officer Research • DOROTHY J. FRAPWELL, J.D., Vice President and • AMY C. WARNER, M.A., Vice Chancellor for General Counsel External Affairs • G. FREDERICK GLASS, J.D., Vice President and • NORLEEN POMERANTZ, Interim Vice Chancellor Director of Intercollegiate Athletics for Student Life • EDWIN C. MARSHALL, O.D., Vice President for • KENNETH B. DURGANS, Ed.D., Assistant Diversity, Equity, and Multicultural Affairs Chancellor for Diversity, Equity, and Inclusion • PATRICK O’MEARA, Ph.D., Vice President for School of Medicine International Affairs • ORA H.
    [Show full text]
  • SWEDISH KORV CHUCK ROASTS 6 9 Negro Minister Wins Andover
    mmirliPBtpr Eiiynttts UmiUi T H U R S D A Y , DBCSE5BIBBR 28, 1967 Avenge DeUy Net Praee Rm S - The education committee^ of fan fltnn Rural Rsetdewes to pier 1%^ Woek KiMed The Weather me, Restdenee A by the TVC. GamieiiliB 8loleii About Town the Junior Women’s Club* of Damato Seeks 88, u e r door tonight. Low aero to Manchester, Inc., will meet to­ JbxvH Buiktors to eek li« for 10 above. Tomorrow fair. High Roy Wlesa, son of Mr. and night at 8 at the home of Mrs. the extenakm o f a none change Off Oothesliiie Mta. Walter W lm e of 1S7 Ugh In u pper 30e. ise George Thnskl, Wedgewood T P C Permit cn Stone St In Oobober the Police are Investigating the at te «B the dean’s list af theft of aromen’s undergar­ 15,563 D r. HPC approved a sone change, tfnian ObUege, Sdienectad^, ments from a dothesUne at 8 e CUy of VfUage Charm t, w M ln a w requested by Jarvta, on Center N.T. for the first trimester. He For Buildings West St. sometime yesterday. n etattoewl Tickets are still available for and Stone Sts. from Realdence AdvetitolBg oa Page 17) to a freshman at the college, The uhdergarmenta were the VOL. LXXXVn, NO. 75 (TWENTY PAGES—TWO SECTIONS) MANCflBSTBR, CONN.. FRIDAY, DECEMBER 29, 1967 PRICE SEVEN CENTS 1, who aloo the American Legion New Done A to Residence Zone C. and a 1M7 graduate of Man­ A j i sjpplloaitlcn for a epeoial only clothes taken from the tea acalnat Jeuvls wants to extend the Resi- chester High M iool.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7.442,390 B2 Seshi (45) Date of Patent: Oct
    USOO7442390B2 (12) United States Patent (10) Patent No.: US 7.442,390 B2 Seshi (45) Date of Patent: Oct. 28, 2008 (54) METHOD FOR ENHANCING WO WO 03/029432 A2 4, 2003 ENGRAFTMENT OF CELLS USING MESENCHYMAL PROGENTOR CELLS (75) Inventor: Beerelli Seshi, Torrance, CA (US) OTHER PUBLICATIONS (73) Assignee: University of South Florida, Tampa, FL Mestas et al., J. of Immunology, 2004, 172, pp. 2731-238.* (US) Teuveson et al., Immun. Review 1993, N136, pp. 101-107.* (*) Notice: Subject to any disclaimer, the term of this Feldman et al., Transplant. Proc. 1998, 30, 4126-4127.* patent is extended or adjusted under 35 Yamaguchi.Y. etal. “Detection of mutations of p53 tumor suppressor U.S.C. 154(b) by 362 days. gene in pancreatic juice and its application to diagnosis of patients with pancreatic cancer: Comparison with K-ras mutation” Clin. Can. (21) Appl. No.: 10/887,582 Res., 1999, 5:1147-1153. Seshi, B. An integrated approach to mapping the proteome of the (22) Filed: Jul. 9, 2004 human bone marrow stromal cell' Proteomics, 2006, 6:5169-5182. O O McCune, J.M. et al., “The SCID-humouse: murine model for the (65) Prior Publication Data analysis of human hematolymphoid differentiation and function” US 2005/OO59147 A1 Mar 17, 2005 Science, 1988, 241:1632-1639. Minguell, J.J. et al. “Nonstimulated human uncommitted Related U.S. Application Data mesenchymal stem cells express cell markers of mesenchymal and (63) Continuation-in-part of application No. 10/263,419, neural lineages' Stem Cells and Develop., 2005, 14:408-414. filed on Oct.
    [Show full text]
  • X11, X12, What Next…
    X11, X12, What next… And its companion: the ROOT GUI X Architecture 1. The kernel gets an event from an input device and sends it to X. 2. The X server determines which window the event affects and sends it to the clients that have selected for the event in question on that window. 3. The client looks at the event and decides what to do. 4. When the X server receives the rendering request, it sends it to the driver to let it program the hardware to do the rendering. 5. The damage event tells the compositor that something changed in the window and that it has to recomposite the part of the screen where that window is visible. 6. The X server receives the rendering requests from the compositor and either copies the compositor back buffer to the front buffer or does a pageflip. Taken from the Wayland web site (http://wayland.freedesktop.org/architecture.html) X12 • X11 was defined in the middle of the 1980's. Since then, computers have changed almost beyond recognition; the simple framebuffer model used by computers at the time has been replaced programmable graphics hardware that is both complex and powerful. Not only has graphics hardware changed, but the basic processing model has and continues to change; parallelism in core system design is becoming the norm, rather than a special case for 'large' systems. • And that's just talking about desktop systems; now there are smart phones, netbooks, tablets, and probably will shortly be other device types that this author can't imagine (else I'd be working on them...).
    [Show full text]